Do you want to read an article? Please log in or register.
Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial)
Lung Cancer
Related content
Lung Cancer
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
Lung Cancer
Reale ML, Scattolin D, Vitale A, Passiglia F, Grisanti S, Macerelli M, Galetta D, Sini C, Minuti G, Citarella F, Roca E, Agustoni F, Dodi A, Cortinovis D, Belluomini L, Ricciardi S, Veccia A, Pizzutilo EG, Scotti V, Alì G, Mazzoni F, Russo A, Pignataro D, Bulotta A, Piovano P, Sergi C, Bettini A, Genova C, Pavan A, Soto Parra HJ, Ortega C, Pozzessere D, Vavalà T, Chiari R, Zannori C, D'Aveni A, Meoni G, Giannarelli D, Malapelle U, Novello S, Bria E, Pasello G
doi: 10.1016/j.lungcan.2025.108762
RECOMMENDED
Lung Cancer
Surgical and Pathological Results Following Neoadjuvant Nivolumab and Platinum-Based Chemotherapy for Locally Advanced Resectable NSCLC: A Multicentre Real-World Series From England
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Lung Cancer
Brunelli A, Hoffman R, Wotton R, Baijal S, Bhatnagar P, Clarke K, Escriu C, Fakih O, Franks K, Lodhia J, Nardini M, Naidu B, Shackcloth M
doi: 10.1016/j.cllc.2024.12.010
Lung Cancer
Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC
Clin Lung Cancer
Cantor DJ, Nimeiri H, Horn L, West M, Ben-Shachar R, Huerga I, Patel JD, Aggarwal C
doi: 10.1016/j.cllc.2025.05.007
RECOMMENDED
Lung Cancer
Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Front Oncol
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M
doi: 10.3389/fonc.2025.1526931
RECOMMENDED
Lung Cancer
Impact of Different Mediastinal Staging Modalities on Target Volume Delineation in Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the Multicenter Randomized PET-Plan Trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Int J Radiat Oncol Biol Phys
Rimner A, Dejonckheere CS, Sahlmann J, Barth SA, Schimek-Jasch T, Adebahr S, Hecht M, Waller CF, Schmid S, Stolz D, Miederer M, Brose A, Binder H, König J, Grosu AL, Nestle U, Gkika E
doi: 10.1016/j.ijrobp.2025.02.041
RECOMMENDED
Lung Cancer
Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Kalkhoran HA, Verschueren MV, Peters BJM, van de Garde EMW, Smit EF, Bohringer S, Cohen D, Gulikers JL, Codrington H, Guchelaar HJ, Visser LE, Zwaveling J
doi: 10.1016/j.cllc.2025.07.009
RECOMMENDED
Lung Cancer
Real-World Efficacy and Safety of Atezolizumab for Advanced Non-Small Cell Lung Cancer in Japan: A Retrospective Multicenter Analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
J Clin Med
Okada M, Ohgino K, Horiuchi K, Sayama K, Arai D, Watase M, Kobayashi K, Terashima T, Ishioka K, Miyawaki M, Sakamaki F, Masuzawa K, Terai H, Yasuda H, Soejima K, Fukunaga K
doi: 10.3390/jcm13247815
RECOMMENDED
Lung Cancer
Impact of Incidental Germline BRCA1/2 and PALB2 Alterations on EGFR Monotherapy Real-World Outcomes for Patients With Advanced Non-Small-Cell Lung Cancer
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Vakkalagadda CV, Bucheit L, Clemens K, Saha J, Zhang N, Patel JD
doi: 10.1016/j.cllc.2025.07.007
Lung Cancer
Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer
Lung Cancer
Vince M, Naqvi SMH, Pellini B, Verbosky M, Melzer D
doi: 10.1016/j.lungcan.2024.107999